Saroglitazar

Name: Saroglitazar in Primary biliary cholangitis: Prevalence of Primary biliary cholangitis
Published: 2026-09-14T15:39:06-04:00

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of Primary biliary cholangitis

1 evidence topic · 1 source

U.S. prevalence

“The adjusted 2021 PBC prevalence was 40.9 per 100,000 adults.” (opens the source at this quote in a new tab)
“for an estimated total of 105,506 adults with PBC in the United States” (opens the source at this quote in a new tab)